人肺腺癌紫杉醇耐药细胞株交叉耐药性实验研究  

Experimental Research of Cross Resistance About Paclitaxel Resistant Human Lung Adenocarcinoma Cell

作　　者：钱军[1] 杨爱珍[1] 陈惠英[1] 徐海军[1] 秦叔逵[1] 

机构地区：[1]解放军第81医院全军肿瘤中心,南京210002

出　　处：《医学研究杂志》2008年第12期52-54,共3页Journal of Medical Research

摘　　要：目的通过建立体外肺腺癌耐药细胞株,研究紫杉醇交叉耐药性,为临床治疗提供有益的实验依据。方法应用浓度递增和短时作用相结合,建立人肺腺癌紫杉醇耐药株SPC-A1/Taxol。通过MTT法检测加入不同药物后耐药细胞的半数抑制浓度,计算耐药指数。结果SPC-A1/Taxol耐药细胞株对多西紫杉醇、长春瑞滨、长春新碱和阿霉素显示高度耐药,对喜树碱类和鬼臼毒素类显示中度或低度耐药,对铂类药物、抗代谢药和中药榄香烯乳未见交叉耐药性。结论SPC-A1/Taxol耐药细胞株为一个较好的多药耐药体外模型,对其交叉耐药性的实验研究可以为临床用药提供有益依据。Objective To investigate paclitaxel cross resistance and provide information for clinical therapy by establishing a paclitaxel resistant human lung adenocarcinoma cell line. Method A paelitaxel resistant human lung adenocarcinoma cell line named with SPC -A1/Taxol was developed by intermittent exposure to gradually increasing concentration of taxol. Resistant index was calculated from median inhibitory concentration （IC50） which was evaluated by MTT assay. Results SPC - A1/Taxol cell line displayed high resistance to taxotere, vinorelbine, vincristine and doxorubicin. It also displayed median or low resistance to eamptothecins and podophyllotoxins. No cross resistance was observed to antitumor platinum and antimetabolite drugs and elemene emusion. Conclusion SPC - A1/Taxol cell line is a typical muhidrug - resistant cell line in vitro. It could be useful for studing the cross resistance and direct clinical medication.

关 键 词：肺肿瘤 多药耐药性 紫杉醇 细胞株 

分 类 号：R978.1[医药卫生—药品] R737.9[医药卫生—药学]